Clonazepam in the treatment of panic disorder with or without agoraphobia: A dose-response study of efficacy, safety, and discontinuance

Journal of Clinical Psychopharmacology

Volumn 17, Issue 5, 1997, Pages 390-400

  Rosenbaum, Jerrold F ^a   Moroz, Georges ^b   Bowden, Charles L ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; PLACEBO;

ADULT; AGORAPHOBIA; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; VERTIGO;

ADOLESCENT; ADULT; AGED; AGORAPHOBIA; CLONAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PANIC DISORDER; PATIENT DROPOUTS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0030777238     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199710000-00008     Document Type: Article

References (27)

1. Ballenger JC, Burrows GD, DuPont RL, Lesser IM, Noyes R, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988;45:413-22.
2. Noyes R Jr, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, Hinrichs JV. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984;41:287-92.
3. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418-23.
4. Spier SA, Tesar GE, Rosenbaum JF, Woods SW. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986;47:238-42.
5. Pollack MH, Tesar GE, Rosenbaum JF, Spier SA. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986;6:302-4.
6. Herman JB, Rosenbaum JF, Brotman AW. The alprazolam to clonazepam switch for the treatment of panic disorder. J Clin Psychopharmacol 1987;7:175-8.
7. Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76.
8. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111-8.
9. Greenblatt DJ, Miller LG, Shader RI. Clonazepam pharmacokinetics, brain uptake, and receptor interactions. J Clin Psychiatry 1987;48[suppl 10]:4-9.
10. Braestrup C, Nielsen M. Benzodiazepine receptors. In; Iversen L, Iversen SD, Snyder SH, eds. Handbook of psychopharmacology. Vol. 17. New York: Plenum, 1983:285-384.
11. Dawson GW, Sue SG, Brogden RN. Alprazolam: a review. Drugs 1984;27:132-47.
12. Fyer AJ, Mannuzza S, Coplan JD. Panic disorders and agoraphobia. In: Kaplan HE, Sadock BJ, eds. Comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams & Wilkins, 1994:1191-204.
13. Rosenbaum JF, Tesar GE. Clonazepam and other anticonvulsants. In: Ballenger JC, ed. Clinical aspects of panic disorder. New York: Wiley-Liss, 1990:259-71.
14. Noyes R, Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991;148:517-23.
15. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF. Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry 1987;144:303-8.
16. Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM, Swinson RP, Weise CC, Maddock RJ, Denahan AQ. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy. J Clin Psychiatry 1995;56:202-20.
17. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:715-22.
18. Stein MB, Hazen AL, Eldridge GD, Walker JR. Structured clinical interview for DSM-III-R, revised for use in Hoffmann-La Roche Anxiety Disorders Program, version 2.1. Manitoba, Canada: University of Manitoba, Anxiety Disorders Research Program, 1992.
19. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured clinical interview for DSM-III-R, version 1.0. Washington DC: American Psychiatric Press, 1990.
20. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education and Welfare, 1976.
21. Williams DA. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971;27:103-17.
22. Merz WA. Placebo response in panic disorder. A review. Eur Psychiatry 1994;9:123-7.
23. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257-63.
24. Cohen LS, Rosenbaum JR. Clonazepam: new uses and potential problems. J Clin Psychiatry 1987;48[suppl 10]:50-5.
25. Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987;144:664-5.
26. Ballenger JC, Pecknold J, Rickels K, Sellers EM. Medication discontinuation in panic disorder. J Clin Psychiatry 1993;54:15-21.
27. Rickels K, Schweizer E, Weiss S, Zovodnick S. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61-8.